October 23rd 2023
Celltrion’s Zymfentra is subcutaneous version of infliximab.
Proliferation of Biosimilars Could Be Costly for Oncologists, Warns Texas Oncology Policy Leader
September 28th 2020Texas Oncology Executive Vice President Debra Patt says it will be unrealistically expensive for oncologists to keep many biosimilars for the same innovator product in their inventories.
Read More
When Will Biosimilars Start Making a Serious Difference in Oncology?
August 5th 2020It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.
Read More
Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars
July 2nd 2020Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars.
Read More